SWOG clinical trial number
SWOG-8240

Evaluation of Spiorgermanium (NSC-192965) in the Treatment of Metastatic Malignant Melanoma

Closed
Phase
Published
Abbreviated Title
Evaluation of Spiorgermanium (NSC-192965) in the Treatment of Metastatic Malignant Melanoma
Activated
11/14/1983
Closed
05/31/1986

Publication Information Expand/Collapse

2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

2001

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

JM Unger;LE Flaherty;PY Liu;KS Albain;VK Sondak Cancer 91(6):148-1155

1987

Phase II evaluation of spirogermanium in malignant melanoma: ASouthwest Oncology Group study.

JW Goodwin;K Kopecky;M Slavik;BL Tranum;SP Balcerzak;WS Fletcher;JJ Costanzi Cancer Treat Rep 71(10):985-986